Emerging opportunities and concerns for drug discovery at serotonin 5-5-HT2B receptors

Current Topics in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 493-503

  Brea, José ^a   Castro Palomino, Julio ^b   Yeste, Sandra ^c   Cubero, Elena ^c   Párraga, Antonio ^c   Domínguez, Eduardo ^a,d   Loza, María Isabel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Edifici Hèlix   (Spain)

^c Laboratorios Dr Esteve SA   (Spain)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; BF 1; CABERGOLINE; DEXFENFLURAMINE; EGIS 7625; FENFLURAMINE; MT 500; NORFENFLURAMINE; PERGOLIDE; PRX 08066; RS 127445; SB 215505; SEROTONIN 2 ANTAGONIST; SEROTONIN 2B ANTAGONIST; SEROTONIN 2B RECEPTOR; TERGURIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; BONE MASS; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; MIGRAINE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; STOMACH FUNCTION; STRUCTURE ACTIVITY RELATION; VALVULAR HEART DISEASE;

DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950555316     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791111524     Document Type: Article

References (103)

1. Sanger, G. J. 5-hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol. Sci., 2008, 29, 465-471.
2. 2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol, 1994, 112, 323-331.
3. Vane, J. R. A. sensitive method for the assay of 5-hydroxytryptamine. Br. J. Pharmacol. Chemother., 1957, 12, 344-349.
4. Clineschmidt, B. V.; Reiss, D. R.; Pettibone, D. J.; Robinson, J. L. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J. Pharmacol. Exp. Ther., 1985, 235, 696-708.
5. Enguix, M. J.; Sanchez, L.; Villazon, M.; Brea, J.; Tristan, H.; Carancho, H. J.; Cadavid, M. I.; Loza, M. I. Differential regulation of rat peripheral. 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 368, 79-90.
6. 2B receptors in rat stomach fundus. Biochem. Pharmacol, 2003, 66, 927-937.
7. Horton, Y. M.; Lubbert, H.; Houslay, M. D. Localization of the gene for the human serotonin 5-HT(2B) receptor to chromosome 2. Mol. Membr. Biol., 1996, 13, 29-31.
8. 2 and stomach fundus serotonin receptor genes. Neuroreport, 1992, 3, 345-348.
9. Kursar, J. D.; Nelson, D. L.; Wainscott, D. B.; Baez, M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol. Pharmacol., 1994, 46, 227-234.
10. 2-like receptor. Expression in brain, heart and intestine. FEBS Lett, 1992, 312, 203-207.
11. 1D receptors. FEBS Lett., 1994, 352, 393-399.
12. 2B serotonin receptor. FEBS Lett., 1994, 342, 85-90.
13. 2C receptors. Br. J. Pharmacol, 1995, 115, 622-628.
14. Kursar, J. D.; Nelson, D. L.; Wainscott, D. B.; Cohen, M. L.; Baez, M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol. Pharmacol., 1992, 42, 549-557.
15. Roth, B. L.; Willins, D. L.; Kristiansen, K.; Kroeze, W. K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther., 1998, 79, 231-257.
16. Ullmer, C.; Schmuck, K.; Kalkman, H. O.; Lubbert, H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett., 1995, 370, 215-221.
17. 2B receptor subtypes in dog. Eur. J. Pharmacol, 2005, 513, 181-192.
18. Glusa, E.; Pertz, H. H. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br. J. Pharmacol, 2000, 130, 692-698.
19. 2B receptor: homologous subtype or species variant? Behav. Brain Res., 1996, 73, 253-257.
20. 2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett, 1996, 391, 45-51.
21. Elangbam, C. S.; Lightfoot, R. M.; Yoon, L. W.; Creech, D. R.; Geske, R. S.; Crumbley, C. W.; Gates, L. D.; Wall, H. G. 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J. Histochem. Cytochem., 2005, 53, 671-677.
22. 2B receptors are expressed by neuronal precursors in the enteric nervous system of fetal mice and promote neuronal differentiation. Ann. N. Y. Acad. Sci., 1998, 861, 246.
23. Westbroek, I.; van der, P. A.; de Rooij, K. E.; Klein-Nulend, J.; Nijweide, P. J. Expression of serotonin receptors in bone. J. Biol. Chem., 2001, 276, 28961.-28968.
24. Zhang, H.; Zhang, T.; Wang, L.; Teng, K. Immunohistochemical location of serotonin and serotonin 2B receptor in the small intestine of pigs. Acta Histochem., 2009, 111, 35-41.
25. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology, 1999, 38, 1083-1152.
26. 2C receptors in. CHO-K1 cells. Br. J. Pharmacol, 1999, 128, 13-20.
27. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci., 1995, 16, 232-238.
28. Jarpe, M. B.; Knall, C.; Mitchell, F. M.; Buhl, A. M.; Duzic, E.; Johnson, G. L. [D-Arg1, D-Phe5, D-Trp7, 9, Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J. Biol Chem., 1998, 273, 3097-3104.
29. Kenakin, T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci., 2007, 28, 407-415.
30. Urban, J. D.; Clarke, W. P.; von, Z. M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Then, 2007, 320, 1-13.
31. 2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur. J. Pharmacol, 2008, 594, 32-38.
32. Deraet, M.; Manivet, P.; Janoshazi, A.; Callebert, J.; Guenther, S.; Drouet, L.; Launay, J. M.; Maroteaux, L. The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine 2B receptor is a gain of proliferative functions. MoI. Pharmacol, 2005, 67, 983-991.
33. Wang, H. Y.; Eberle-Wang, K.; Simansky, K. J.; Friedman, E. Serotonin-induced muscle contraction in rat stomach fundus is mediated by a G alpha z-like guanine nucleotide binding protein, J. Pharmacol Exp. Ther., 1993, 267, 1002-1011.
34. Cox, D. A.; Cohen, M. L. 5-Hydroxytryptamine2B receptor signaling in rat stomach fundus: role of voltage-dependent calcium channels, intracellular calcium release and protein kinase C. J. Pharmacol Exp. Ther., 1995, 272, 143-150.
35. 2B receptor signaling in the rat stomach fundus: dependence on calcium influx, calcium release and protein kinase C. Behav. Brain Res., 1996, 73, 289-292.
36. Cohen, M. L.; Wittenauer, L. A. Serotonin receptor activation of phosphoinositide turnover in uterine, fundai, vascular, and tracheal smooth muscle. J. Cardiovasc. Pharmacol, 1987, 10, 176-181.
37. 2B receptor-mediated contraction in the rat stomach fundus? Life Sci., 1995, 56, L333-L338.
38. 2B receptor activation stimulate phospholipase D activity in the rat stomach fundus. Prog. Neuropsychopharmacol. Biol Psychiatry, 1999, 23, 697-704.
39. Tournois, C.; Mutel, V.; Manivet, P.; Launay, J. M.; Kellermann, O. Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism, J. Biol. Chem., 1998, 273, 17498-17503.
40. Manivet, P.; Mouillet-Richard, S.; Callebert, J.; Nebigil, C. G.; Maroteaux, L.; Hosoda, S.; Kellermann, O.; Launay, J. M. PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J. Biol. Chem., 2000, 275, 9324-9331.
41. 2B receptor. J. Biol. Chem., 1996, 271, 3141-3147.
42. 2B receptor-mediated serotonin trophic functions. Ann. N. Y. Acad. Sci., 1998, 861, 67-73.
43. 2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development, 1997, 124, 1745-1755.
44. Bhasin, N.; Kernick, E.; Luo, X.; Seidel, H. E.; Weiss, E. R.; Lauder, J. M. Differential regulation of chondrogenic differentiation by the serotonin2B receptor and retinote acid in the embryonic mouse hindlimb. Dev. Dyn, 2004, 230, 201-209.
45. Nebigil, C. G.; Launay, J. M.; Hickel, P.; Tournois, C.; Maroteaux, L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc. Natl. Acad. Sci. USA, 2000, 97, 2591-2596.
46. 2B receptor signaling in serotonergic neuronal cells. FASEB J., 2006, 20, 1843-1854.
47. 2B receptors are required for 3, 4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neuroaci., 2008, 28, 2933-2940.
48. 2B receptor by the subtype-selective antagonist SB-215505. Br. J. Pharmacol, 2004, 142, 1332-1342.
49. 2B receptors. Gastroenterology, 2007, 133, 897-906.
50. Borman, R. A.; Tilford, N. S.; Harmer, D. W.; Day, N.; Ellis, E. S.; Sheldrick, R. L.; Carey, J.; Coleman, R. A.; Baxter, G. S. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br. J. Pharmacol, 2002, 135, 1144-1151.
51. Jaffre, F.; Bonnin, P.; Callebert, J.; Debbabi, H.; Setola, V.; Doly, S.; Monassier, L.; Mettauer, B.; Blaxall, B. C.; Launay, J. M.; Maroteaux, L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ. Res., 2009, 104, 113-123.
52. 2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation, 2004, 110, 969-974.
53. 2B receptor: possible involvement in trophic functions of serotonin. Cell Mol. Biol., 1994, 40, 403-411.
54. Lauder, J. M.; Wilkie, M. B.; Wu, C.; Singh, S. Expression of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in the mouse embryo. Int. J. Dev. Neurosci., 2000, 18, 653-662.
55. Monassier, L.; Laplante, M. A.; Jaffre, F.; Bousquet, P.; Maroteaux, L.; de, C. J. Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension, 2008, 52, 301-307.
56. Kaumann, A. J.; Levy, F. O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther., 2006, 111, 674-706.
57. Launay, J. M.; Herve, P.; Peoc'h, K.; Tournois, C.; Callebert, J.; Nebigil, C. G.; Etienne, N.; Drouet, L.; Humbert, M.; Simonneau, G.; Maroteaux, L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med., 2002, 8, 1129-1135.
58. 2B receptor antagonist. Cardiovasc. Drugs Ther., 2003, 17, 427-434.
59. Twarog, B. M.; Page, I. H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol, 1953, 175, 157-161.
60. Lin, Z.; Walther, D.; Yu, X. Y.; Drgon, T.; Uhl, G. R. The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics, 2004, 14, 805-811.
61. 2B receptor activation regulates neonatal respiratory activity in vitro. J. Neurobiol, 2006, 66, 949-961.
62. Knowles, I. D.; Ramage, A. G. Evidence that activation of central 5-HT(2B) receptors causes renal sympathoexcitation in anaesthetized rats. Br. J. Pharmacol, 2000, 129, 177-183.
63. 1B, and ketanserin-sensitive receptors. Endocrinology, 2007, 148, 4509-4522.
64. Bhasin, N.; LaMantia, A. S.; Lauder, J. M. Opposing regulation of cell proliferation by retinoic acid and the serotonin2B receptor in the mouse frontonasal mass. Anat Embryol., (Bert) 2004, 208, 135-143.
65. Fiorica-Howells, E.; Maroteaux, L.; Gershon, M. D. Serotonin and the 5-HT(2B) receptor in the development of enteric neurons. J. Neurosci., 2000, 20, 294-305.
66. Gershon, M. D. V. Genes, lineages, and tissue interactions in the development of the enteric nervous system. Am. J. Physiol, 1998, 275(5 Pt 1), G869-G873.
67. Dizeyi, N.; Bjartell, A.; Hedlund, P.; Tasken, K. A.; Gadaleanu, V.; Abrahamsson, P. A. Expression of serotonin receptors 2B and. 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur. Urol., 2005, 47, 895-900.
68. Brouland, J. P.; Manivet, P.; Brocheriou-Spelle, I.; Wassef, M.; Le Bodic, M. F.; Lavergne, A.; Launay, J. M. Histological, immunohistochemical, ultrastructural and biochemical study of human gastric composite tumor: expression of the serotonin-2B receptor by the neuroendocrine component. Endocr. Pathol, 2001, 12, 77-86.
69. 2 activation, Cell Signal, 2006, 18, 628-639.
70. Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med., 2007, 356, 6-9.
71. 2B receptor and 5-HT transporter transcript changes in Sprague-Dawley rats. Exp. Toxicol. Pathol, 2008, 60, 253-262.
72. Fitzgerald, L. W.; Burn, T. C.; Brown, B. S.; Patterson, J. P.; Corjay, M. H.; Valentine, P. A.; Sun, J. H.; Link, J. R.; Abbaszade, I.; Hollis, J. M.; Largent, B. L.; Hartig, P. R.; Hollis, G. F.; Meunier, P. C.; Robichaud, A. J.; Robertson, D. W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol., 2000, 57, 75-81.
73. 2B receptor. Mol. Pharmacol., 2005, 68, 20-33.
74. Hong, Z.; Olschewski, A.; Reeve, H. L.; Nelson, D. P.; Hong, F.; Weir, E. K. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am. J. Physiol Lung Cell Mol. Physiol., 2004, 286, L531-L538.
75. Ni, W.; Li, M. W.; Thakali, K.; Fink, G. D.; Watts, S. W. The fenfluramine metabolite (+) norfenfluramine is vasoactive. J. Pharmacol. Exp. Ther., 2004, 309, 845-852.
76. Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med., 2007, 356, 29-38.
77. Zanettini, R.; Antonini, A.; Gatto, G.; Gentile, R.; Tesei, S.; Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med., 2007, 356, 39-46.
78. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology, 1997, 36, 793-802.
79. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology, (Berl) 1995, 118, 178-182.
80. 2B receptor agonist, BW 723C86, on three rat models of anxiety. Br. J. Pharmacol, 1996, 117, 1443-1448.
81. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol, 1996, 117, 427'-434.
82. 2B receptor mediated. Neuropharmacology, 1998, 37, 1603-1610.
83. Murray, F.; Hutson, P. H. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur. J. Pharmacol., 2007, 569, 41-47.
84. 2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology (Berl), 2005, 179, 418-429.
85. Setola, V.; Hufeisen, S. J.; Grande-Allen, K. J.; Vesely, I.; Glennon, R. A.; Blough, B.; Rothman, R. B.; Roth, B. L. 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol., 2003, 63, 1223-1229.
86. 2B antagonists structures, activities and potential therapeutic applications. Mini. Rev. Med. Chem., 2004, 4, 325-330.
87. 2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties. Bioorg. Med. Chem. Lett., 2009, 19, 2206-2210.
88. 2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ. Res., 2009, 104, 1-3.
89. Panconesi, A.; Sicuteri, R. Headache induced by serotonergic agonists-a key to the interpretation of migraine pathogenesis? Cephalalgia, 1997, 17, 3-14.
90. 2B receptor antagonist. Br. J. Pharmacol., 1999, 127, 1075-1082.
91. Antimigraine Drugs. RS-127445; Drug Data Report, 1999, 21, 577-663.
92. 2B receptor antagonists. PCT Int. Appl. WO2003035646 May 1, 2003.
93. Spiller R. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Curr. Opin. Pharmacol, 2008, 8, 709-714.
94. 2B/c receptor antagonist SB-206553. J. Pharmacol. Exp. Ther., 2009, 328, 766-776.
95. McLean, P. G.; Coupar, I. M.; Molenaar, P. Changes in sensitivity of 5-HT receptor mediated functional responses in the rat oesophagus, fundus and jejunum following chronic infusion with 5-hydroxytryptamine. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 354, 513-519.
96. Hasuo, H.; Matsuoka, T.; Akasu, T. Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus. J. Neurosci., 2002, 22, 7509-7517.
97. Dumitrascu, R.; Kulcke, C.; Kouri, F.; Ghofrani, H.A.; Reiter, R.; Weissmann, N.; Seeger, W.; Grimminger, F.; Eickelberg, O.; Schermuly, R.T. Terguride reverses monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care. Med., 2008, 177(Abstracts Issue): A695.
98. Ergonex. Web site. www.ergo.nex.com
99. Predix. Web site. www.predixpharma.com
100. Epix. Web site. www.epixpharma.com
101. 2 receptor ligands. PCT Int. Appl., WO 2004089312 Oct 21, 2004.
102. 2B modulators. PCT Int. Appl., WO2006034511 Mar 30, 2006.
103. Bruton, G.; Hirst, D. Quinoline derivatives with affinity for the 5-HT2B receptor. PCT Int. Appl., WO 2009080675 Jul 2, 2009.